We investigated the cytotoxic effects of BCL2 and BCR-ABL1 kinase inhibition by Venetoclax and Nilotinib, alone or in combination, on self-renewal properties of primitive CP-CML cells. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.